<div><div></div><div><span><ul><li><span>According to estimates from 11 analysts, Roivant Sciences Ltd. stock's average price target has risen from $35.71 to $36.23, with forecasts ranging from $29.5 to $41 per share</span></li><li><span>Based on the May 19 closing price, the updated target implies approximately 28% potential upside</span></li><li><span>Consensus rating remains at “Buy” across 13 covering analysts, with 12 Buys, 1 Holds and 0 Sells</span></li></ul><p><span>Explore more price target data and ratings for Roivant Sciences Ltd. on the </span><span>, and track all previous and future analyst recommendations for Roivant Sciences Ltd. in the dedicated </span>News Flow<span>.</span></p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.</span></div></section></span></div></div>

ROIV

<p>Roivant Sciences Ltd.'s stock price target has been raised to $36.23, indicating a potential upside of 28%. The average target increased from $35.71, with estimates ranging from $29.5 to $41 per share. The consensus rating remains 'Buy' from 13 analysts, including 12 Buys and 1 Hold.</p>

TradingView

Roivant Sciences

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Health Care Select Sector SPDR

iShares US Pharma

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

SPDR S&P Biotech

VG Health

Factset Research

Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.23, Implies 28% Upside